Ser413

Site Information
DDPTAGRsNAPITAP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4273339

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 4 , 5 )
Disease tissue studied:	melanoma skin cancer ( 1 )
Relevant cell line - cell type - tissue:	HeLa (cervical) ( 2 ) , HeLa S3 (cervical) ( 5 ) , HeLa_Meta (cervical) ( 4 ) , HeLa_Pro (cervical) ( 4 ) , HeLa_Telo (cervical) ( 4 ) , WM239A (melanocyte) ( 1 )

Upstream Regulation
Treatments:	MG132_withdrawal ( 4 )

References
1	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
2	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
3	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
4	Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81 20097925 Curated Info
5	Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48 18691976 Curated Info